Yuhan Corporation Presents Phase 1b Results for Lesigercept, an Investigational Allergy Treatment
Yuhan Corporation announced on June 15 that it presented Phase 1b results for lesigercept, an investigational treatment for allergic rhinitis, according to a company press release. The trial evaluated the drug’s safety and tolerability in adults with seasonal allergic rhinitis, with preliminary data showing a favorable safety profile and evidence of biological activity.
What Is Lesigercept?
Lesigercept is a recombinant human interleukin-4 receptor antagonist designed to block the activity of interleukin-4, a protein involved in allergic inflammation. By targeting this pathway, the drug aims to reduce symptoms such as nasal congestion, sneezing, and itching associated with allergic rhinitis. The Phase 1b trial, conducted across multiple sites in South Korea, enrolled 60 participants who received varying doses of lesigercept over a four-week period.
What Were the Trial Results?
According to Yuhan’s preliminary data, lesigercept demonstrated a favorable safety profile, with no serious adverse events reported. Mild to moderate side effects, including injection-site reactions and transient fatigue, were observed in a small number of participants. The trial also showed a dose-dependent reduction in markers of allergic inflammation, such as eosinophil counts, suggesting the drug may modulate the immune response effectively.
What Are the Next Steps?
Yuhan plans to advance lesigercept to Phase 2 trials, which will focus on assessing its efficacy in larger patient populations. The company emphasized that the Phase 1b results support further development, though no timeline for regulatory submissions has been announced. “These findings provide a strong foundation for evaluating lesigercept’s potential as a novel treatment for allergic rhinitis,” said a spokesperson for Yuhan.
How Does This Fit Into the Allergy Treatment Landscape?
Allergic rhinitis affects over 400 million people globally, with current treatments including antihistamines, nasal corticosteroids, and immunotherapy. Lesigercept’s mechanism of action differs from existing options, targeting a specific inflammatory pathway. While Phase 1b data are preliminary, the drug’s unique approach could offer an alternative for patients who do not respond to conventional therapies.
What Do Experts Say?
Dr. Sarah Lin, an allergist at the Mayo Clinic, noted that “targeted biologics like lesigercept represent a promising direction in allergy treatment. However, larger trials are needed to confirm long-term safety and efficacy.” The American College of Allergy, Asthma, and Immunology (ACAAI) has not yet commented on the trial results.
For more information, visit Yuhan Corporation’s official website.
Keep reading